ANCR Animalcare Group Plc

The Company issued 8,602,150 new ordinary shares in total pursuant to the Fundraise, representing approximately 14.2% of the Company's existing issued ordinary shares prior to the Fundraise.

Settlement and admission of the Placing Shares took place at 8.00 am on 5 December 2024.

As set out in the Fundraise Announcement the proceeds of the Fundraise (net of transaction costs) will be used to part fund the cash consideration payable by the Company for the conditional acquisition of the entire issued share capital of Randlab Pty Ltd, Randlab Australia Pty Ltd (and its wholly-owned subsidiary, Randlab (New Zealand) Limited) and Randlab Middle East Veterinary Medicine Trading Single Owner L.L.C. , a privately-owned Australian-based equine veterinary business (the "Acquisition"). The Fundraise will also enable the Company to maintain an appropriate leverage position that enables Animalcare to continue to invest in its growth strategy, including future inorganic investment opportunities.

The aggregate gross proceeds from the Fundraise amounted to approximately £20 million.

The Issue Price of 232.5 pence per Placing Share represented a 5.1% discount to the closing price on 2 December 2024.

Soft pre-emption has been adhered to in the allocations process, where possible. The Company was involved in the allocations process, which has been carried out in compliance with the MIFID II Allocation requirements.

Stifel and the Company undertook a pre-launch wall-crossing process, including consultation with certain major shareholders, to the extent reasonably practicable and permitted by law.

Following discussions between Stifel and the Company, it was decided that a retail offer would not be included in the Placing. The Placing structure was chosen to minimise time to completion and complexity.